BIO
The table below shows Bio-Rad Laboratories, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B |
| Cost of revenue | $1.24B | $1.19B | $1.24B | $1.23B | $1.28B | $1.11B |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B |
| R&D | $275.60M | $295.90M | $247.40M | $256.90M | $260.64M | $217.76M |
Bio-Rad Laboratories, Inc. reported annual revenue of $2.58B for fiscal year 2025. That is up 0.7% from $2.57B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $2.07B (FY 2016) to $2.58B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $844.30M |
| $814.00M |
| $841.70M |
| $827.80M |
| $877.12M |
| $798.80M |
| Operating income | $47.20M | $269.00M | $337.80M | $482.60M | $500.34M | $421.33M |
| Income tax | $235.60M | -$498.30M | -$212.80M | -$1.08B | $1.19B | $1.10B |
| Net income | $759.90M | -$1.84B | -$637.30M | -$3.63B | $4.25B | $3.81B |
| EPS (diluted) | $27.85 | -$65.36 | -$21.82 | -$121.79 | $140.83 | $126.47 |